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Background: To analyze our experience with intraoperative electron radiation therapy (IOERT) followed by
moderate doses of external beam radiation therapy (EBRT) in patients with locally recurrent renal cell carcinoma.
Methods: From 1992 to 2010, 17 patients with histologically proven, locally recurrent renal cell carcinoma
(median tumor size 7 cm) were treated by surgery and IOERT with a median dose of 15 Gy. All patients met the
premise of curative intent including 7 patients with oligometastases at the time of recurrent surgery, which were
resected and/or irradiated. The median time interval from primary surgery to local recurrence was 26 months. Eleven
patients received additional 3D-conformal EBRT with a median dose of 40 Gy.
Results: Surgery resulted in free but close margins in 6 patients (R0), while 9 patients suffered from microscopic (R1)
and 2 patients from macroscopic (R2) residual disease. After a median follow-up of 18 months, two local recurrences
were observed, resulting in an actuarial 2-year local control rate of 91%. Eight patients developed distant failures,
predominantly to liver and bone, resulting in an actuarial 2-year progression free survival of 32%. An improved PFS rate
was found in patients with a larger time interval between initial surgery and recurrence (> 26 months). The actuarial
2-year overall survival rate was 73%. Lower histological grading (G1/2) was the only factor associated with improved
overall survival. Perioperative complications were found in 4 patients. No IOERT specific late toxicities were observed.
Conclusions: Combination of surgery, IOERT and EBRT resulted in high local control rates with low toxicity in patients
with locally recurrent renal cell cancer despite an unfavorable surgical outcome in the majority of patients. However,
progression-free and overall survival were still limited due to a high distant failure rate, indicating the need for
intensified systemic treatment especially in patients with high tumor grading and short interval to recurrence.
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Renal cell carcinoma (RCC) is the most common type of
kidney cancer in adults [1]. Surgery represents the corner-
stone of approaches with curative intent treatment and
even plays a role in primary metastatic disease [2]. How-
ever, even in patients receiving curative surgery for local-
ized disease at presentation, overall survival is limited,
mainly due to the high rates of early distant rather than
local failures. Therefore the main recent research efforts
focused on the development of adjuvant systemic therap-
ies rather than intensification of local treatment for ex-
ample by adjuvant irradiation, which showed no survival* Correspondence: gregor.habl@med.uni-heidelberg.de
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stated.benefit according to randomized trials during the 1970s
and 80s [3-5].
However, a small fraction of patients reported to be in
the range of 0-17% depending on initial tumor size [6], will
develop an isolated local recurrence without evidence of
distant spread after curative surgery. As these patients
have obviously not developed early metastatic spread, they
reasonably represent a patient group for a salvage treat-
ment approach with curative intent.
In contrast to primary disease, local recurrences of renal
cell carcinomas share some features with other tumor
entities located in the renal fossa, especially soft tissue
sarcoma [7]. Both often present as large tumor masses
directly adjacent to vital structures or the abdominal wall,
and thus limit the surgical ability to achieve wide resection
margins. However, resection margin has been reported asd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Lesion and treatment characteristics
n % n %
Age EBRT
Median 61 Yes 11 65
Range 32-76 No 6 35
Gender EBRT dose
Male 11 65 Median 40
Female 6 35 Range 36-43,2
Time to rec. Adj. CHT
Median 26 Yes 2 12
Range 2-115 No 15 88
Histology Resection margin
Clear cell 14 82 R0 6 35
Papillary 2 12 R1 9 53
Sarcomatoid 1 6 R2 2 12
Tumor size IORT dose
Median 7 Median 15
Range 3-14 Range 10-20
Grading IORT energy
G1/2 13 76 Median 8
G3 4 24 Range 6-12
Distant met.* IORT cone
Yes 7 41 Median 10
No 10 59 Range 6-18
Age: [years], Time to rec. : Time from surgery of primary lesion until surgery for
recurrent lesion [months], Tumor Size: [cm], Distant Met: History of distant
metastasis prior to or at actual treatment, EBRT: External Beam Radiation Therapy,
IORT: Intraoperative Radiation Therapy, EBRT/IORT dose: [Gy], adj CHT : adjuvant
Chemotherapy (actual treatment), IORT Energy: [MeV], IORT cone: [cm].
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survival not only for retroperitoneal sarcoma, but also in
patients experiencing an isolated local recurrence of renal
cell cancer [8]. Therefore it seems reasonable to consider
similar additional local therapies like radiation therapy for
both patients groups. Unfortunately, they also share the
feature of low radiation sensitivity while being surrounded
by organs at risk with low radiation tolerance like stom-
ach, small bowel, contralateral kidney, liver and spinal
cord. Using external beam radiation alone would lead to
dose limitations with restricted efficacy or considerable
toxicity, especially if conventional radiation techniques are
used [5].
Intraoperative electron radiation (IOERT) is a technique
which includes the possibility to surgically displace organs
at risk with low radiation tolerance from the target volume
while applying a large single dose to the regions at high
risk for incomplete resection. Thus, IOERT offers the
possibility to overcome these dose limitations, especially if
combined with moderate doses of postoperative external
beam radiation therapy. Therefore IOERT has been intro-
duced in the treatment of retroperitoneal tumors at our
center more than two decades ago and has been shown to
result in increased local control at least for sarcoma
patients by our and other research groups [7,9].
For these reasons, we offered our patients with locally
recurrent renal cell carcinoma a similar multimodality
treatment approach. It consisted of maximal surgery and
IOERT followed by moderate doses of postoperative EBRT
in order to avoid severe radiation side effects to abdominal
organs at risk while escalating the dose to the tumor bed
to improve local control.
In this work we present our experience using this
approach based on a retrospective evaluation.
Methods
Between 1992 and 2010, 17 patients with histologically
proven recurrent renal cell carcinoma were treated in our
institution with surgery and IOERT boost +/− postopera-
tive EBRT. All recurrences were located in the renal fossa.
The median time interval from primary surgery to recur-
rence was 26 month (2–115 months). All patients were
restaged with at least abdominal CT or MRI and x-rays of
the lung. Further imaging to exclude distant metastases
took place in case of clinical suspicion. Patients were
selected for this multimodality approach by a surgeon and
radiation oncologist. Indication for IOERT was seen if
complete surgical removal with microscopic free margins
seemed impossible or at least questionable, although gross
complete resection was attempted in all cases. Seven of
the 17 patients showed limited metastatic disease, which
was attempted for resection and/or irradiation. Hence, all
patients met the premise of curative intent treatment.
Further patient characteristics are shown in Table 1.IOERT was performed in a dedicated operating room
with an integrated Siemens Mevatron ME linear acceler-
ator (Siemens, Concord, CA). The IOERT dose was pre-
scribed to the 90% isodose level and the IOERT field was
selected to cover the area of suspected microscopic re-
sidual disease. After defining the target area in coordin-
ation with the surgeon, an applicator with appropriate
diameter was chosen, manually positioned and attached
to the table. Lead shields of 5 mm thickness could be
used to protect or displace uninvolved tissue. The pa-
tient was then located beneath the linear accelerator and
the applicator was aligned by a laser air-docking system
at a focus-to-surface distance of 100 cm. The electron
energy was selected according to the depth of tissue to
be irradiated. The median IOERT dose was 15 Gy, using
a median electron energy of 8 MeV, with a median appli-
cator size of 10 cm. Dose prescription was based on sur-
geons assessment of margin status including increasing
but not routine use of intraoperative pathologic assess-
ment of frozen sections during the overall study period.
In general, higher IOERT doses were applied in cases
Figure 1 Actuarial local control rate.
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to the. surgeons assessment. In 11 patients, additional post-
operative 3D-conformal EBRT was applied with a median
dose of 40 Gy in conventional fractionation. Six patients
received no EBRT due to postoperative complications or
patient´s refusal. Only 2 patients received adjuvant sys-
temic therapy. For detailed treatment characteristics see
Table 1.
Follow-up examinations took place in our institution
and/or the Department of Urology. Patients lost to rou-
tine follow-up were contacted by phone. Local recur-
rence was defined as tumor growth in the renal fossa.
Progression-free survival was defined as absence of
local/distant failure or death from any cause. Overall
survival was defined as absence of death from any cause.
Toxicities from surgery, IOERT and EBRT were pooled
because of the difficulty to precisely distinguish between
the toxicity caused by each separate treatment. Descrip-
tive statistics and Kaplan-Meier estimation analysis were
applied for statistical workup. The 1- and 2-year actuarial
rates for local control, progression-free survival and over-
all survival for the entire group and various subgroups
were calculated. Statistical differences in time-to-event
data were tested by the log rank test. Relations between
distinct parameters were tested for significance by Fisher´s
exact test. Differences were considered statistically signifi-
cant for a p-value of ≤ 0.05. The study is in compliance
with the Declaration of Helsinki (Sixth Revision, 2008).
Furthermore, the study was approved by the Independent
Ethics committee of the Medical Faculty at the University
of Heidelberg.Figure 2 Actuarial progression free survival rate.Results
Complete surgical removal with free margins (R0) was
achieved in only six patients. Nine patients showed involved
margins (R1) and in two patients gross residual disease (R2)
was present. Subgroup analyses revealed statistically signifi-
cant associations between tumor size < 7 cm (p = 0,035) or
resection of adjacent organs (p = 0,035) with an increased
probability of microscopic complete resections.
After a median follow-up of 18 months (2–211 months),
two local recurrences were observed in the entire group,
resulting in actuarial 1- and 2-year local control rates of
91%, respectively (Figure 1). The recurrences were classi-
fied as one infield-IOERT and one outfield-EBRT field
recurrence. No factors could be established as significantly
predictive for local control in the subgroup analyses.
Interestingly, two of the seven patients with limited dis-
tant metastases at time of recurrent surgery were among
the three patients with survival times of more than
15 years, indicating that long-term survival is possible if
adequate local control is achieved even in patients with
unfavorable disease situations.Eight patients developed new distant metastasis, mainly
to liver (29%) and bone (24%). The resulting actuarial 1-
and 2-year progression free survival rate for the entire
group was 49% and 32% (Figure 2). Univariate subgroup
analyses revealed a significantly improved progression free
survival rate in patients with a time interval between initial
surgery and recurrence >26 months (p = 0.015).
The actuarial 1- and 2-year overall survival rates were
81% and 73%, respectively (Figure 3). Lower histological
grade (G1/2 vs G3) was the only factor which significantly
correlated with improved overall survival (p = 0,003) ac-
cording to univariate subgroup analyses.
Figure 3 Overall survival.
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larly as wound healing disturbance in one patient and
intraabdominal abscesses in two patients. One patient de-
veloped acute renal failure and hyperglycemia. No severe
acute or late toxicities specifically attributable to IOERT
or EBRT were observed.
Discussion
Treatment approaches with curative intent for renal cell
carcinoma in primary situation mostly consist of surgery
with or without adjuvant systemic therapy due to the
considerable risk for distant failure, which still repre-
sents the limiting factor for improved overall survival.
Radiation therapy is usually not part of the primary
treatment, because the risk of isolated local recurrences
seems much lower than the risk of distant spread and
sufficient radiation doses are hardly achievable with con-
ventional techniques because of the low tolerance of the
surrounding organs at risk. Consequently, randomised
trials evaluating adjuvant radiation therapy during the
1970s and 80s failed to show a survival benefit in com-
parison to surgery alone [3-5], thus limiting the role of
radiation therapy mainly to palliative situations.Table 2 Outcomes after surgery + IOERT +/− EBRT for primary
Series Primary/recurrent f/u
med (y)
M
do
Pamplona [13] 8/3 0.7 15
San Francisco [14] 0/10 5.9 15
Mayo [10] 3/19 9.9 13
Madrid-Pamplona (pooled) [11] 15/10 22.2 14
Current study 0/17 1.5 15However, a small patient group will develop an isolated
local recurrence after curative intent surgery. As these
patients did not suffer from early distant spread but failed
locally, one may argue in favor of a specific disease stage
with a different tumor biology, which justifies a salvage
treatment approach with curative intent. Although data re-
garding this situation are rare, surgery alone will frequently
result in microscopic or gross positive margins given the
often advanced lesion sizes combined with the unfavorable
localization [10,11]. Even after complete resection, these
patients will be at high risk for local re-recurrence [12],
since wide margins seem hard to achieve, thus leading to
the rationale for additional radiation therapy.
However, as addressed earlier, sufficient radiation doses
to control residual disease seem hardly achievable using ex-
ternal radiation therapy techniques alone, due to the limited
radiation tolerance of adjacent organs at risk. Therefore
several groups including ours have proposed the introduc-
tion of IOERT into the treatment strategy in order to escal-
ate the dose to the high risk regions without compromising
the tolerance of the surrounding tissue, especially small
bowel.
Using a combination of maximum surgery, IOERT
and moderate doses of postoperative external beam
radiation therapy, we observed a highly satisfactory
estimated 2-year local control rate of 91%, especially
regarding the unfavorable surgical outcome with
microscopic or gross residual disease in the majority of
our patients. Moreover, this approach was not accom-
panied by increased toxicity compared to surgery and
EBRT alone [3-5].
These findings are in line with the reports of other
groups using similar treatment approaches including
IOERT (see Table 2). For example, investigators from
the University of Pamplona reported early outcome data
on 11 patients suffering from locally advanced primary
or recurrent renal cell carcinoma, treated with surgery
and IOERT [13]. Seven patients received additional
external beam radiation therapy with 30–45 Gy. They
observed only one local recurrence and found no add-
itional toxicity due to IOERT in short-term follow-up.
At the University of San Francisco, ten patients with lo-
cally recurrent renal cell cancer have been treated with
surgery plus IOERT. Only two local recurrences were/recurrent renal cell carcinoma
edian IORT
se (Gy)
Median EBRT
dose (Gy)
EBRT
number
3-y
OS (%)
Local
control
30-45 7/15 Not stated 10/11
none 0/10 36 8/10
.5 48 21/22 50 17/22
44 15/25 38 21/25
40 11/17 63 15/17
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groups from Mayo [10] and Madrid-Pamplona [11] also
reported crude local control rates in excess of 80% after
mature follow up (more than 10 years) in the largest
published series on the use of IOERT for locally ad-
vanced or recurrent renal cell cancer, thus indicating
the long-term durability of local control. They also con-
firmed the low overall rates of severe toxicity (less than
20%) with this approach.
These figures compare well with surgery only series, al-
though data on local control with surgery alone are ex-
tremely rare. To our knowledge, Margulis et al. [12]
published the largest series reporting data on local control
after treatment of local recurrences with surgery alone.
After a median follow up of 41 months, they described a
15% rate of isolated local re-recurrences in their series of
54 patients. Another 50% developed distant failure with or
without local failure, indicating an even higher local re-
recurrence rate, although the overall incidence of local re-
recurrences was not stated. The authors further identified a
positive margin resection as a negative predictor of cause-
specific survival in their series. Although not reported pre-
cisely, it can be estimated from their risk model, that less
than one third of their patients had a positive margin com-
pared to two thirds in our cohort. Given the unfavourable
surgical outcome, it therefore seems likely that the addition
of IOERT has contributed to the low incidence of local
recurrences in our and other IOERT series with even higher
rates of margin positive resections [10,11].
However, we observed considerable rates of distant me-
tastases in our cohort, which compromised progression-
free and overall survival. Our results seemed comparable
to the findings of other groups using treatment ap-
proaches with [10,11,13-15] or without IOERT [12,16-19].
For example, Hallemeier et al. [10] reported 1- and 5-year
PFS rates of 64% and 31%, which were mainly influenced
by a high rate of distant failures in their series of patients
treated with surgery and IOERT. Estimated OS-rates at 1
and 5 years were 91% and 40%, respectively. Calvo et al.
[11] described 1- and 5-year PFS rates of 59% and 18%
using a similar treatment approach. Again distant failure
was the major pattern of relapse. Overall survival at 1 and
5 years was 71% and 38%. Margulis et al. [12] found a dis-
tant failure rate of 50% in their series using surgery alone
with additional systemic therapy in 69% of the patients.
Although not stated, 1- and 2-year PFS rates of about 45%
and 32% can be estimated from their published Kaplan-
Meier curves, which are similar to our findings. Neverthe-
less, they reported an impressive median cause-specific
survival of 61 months, though this figure should be inter-
preted with caution since 15% of their patients died of
non-renal cell cancer causes. Similarly Itano et al. [18] de-
scribed a 5-year disease-specific survival of 51% in a sub-
group of 11 patients treated by surgery alone. In contrast,only 4 of 11 patients survived for more than 2 years after
surgery alone in the series of Esrig et al. [19]. Taken
together, progression-free and overall survival in these pa-
tients seem to be mainly limited by distant control with or
without IOERT, although keeping in mind, that such com-
parisons are likely biased by differences in patient selec-
tion. Nevertheless, this raises the question for additional
systemic treatment, which has not been applied to the
majority of our patients.
We identified a short time interval between primary
surgery and recurrence and high histological grading
(G3) as factors associated with poor survival, although
these results should be interpreted with extreme caution
since patient numbers were very small. Especially pa-
tients with the mentioned adverse features may benefit
from early intensified systemic therapy and should there-
fore be excluded at least from the time-consuming post-
operative external beam radiation phase.
Clearly, our study has some limitations, especially re-
garding its retrospective nature, the small patient number
and the rather short follow up. Therefore conclusions
should be drawn with caution. However, given the rarity
of this specific disease situation, adequately powered pro-
spective studies comparing different treatment schedules
seem very unlikely. Therefore publication of all cases and
treatment approaches seems valuable to give treating phy-
sicians as much information as possible for the treatment
of these challenging patients. Further on, our data has
been included into a multi-institutional pooled analysis
led by the MGH group, which mainly confirms our find-
ings in a larger patient group, but so far has been only
published in abstract form [20]. We strongly encourage
other groups to participate in similar efforts.
Conclusion
In summary, our study represents one of the largest
single center series evaluating the role of IOERT in the
treatment of recurrent renal cell carcinoma. Combin-
ation of maximum surgery, IOERT and EBRT resulted
in high local control rates with low toxicity despite an
unfavorable surgical outcome in the majority of pa-
tients. However, progression-free and overall survival
were still limited due to a high distant failure rate, indi-
cating the need for intensified systemic treatment espe-
cially in patients with high tumor grading and short
interval to recurrence.
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